Description of Invention:
A new synthetic peptide, which stimulates secondary immune response to malaria circumsporozite (CS) protein, offers to improve the rational design and construction of more efficacious malaria vaccines. Previously prepared antimalarial vaccines have only been able produce secondary immune response in laboratory animals harboring particular genes. This new peptide sequence stimulates secondary helper T-cells as well as increased antibody production against the CS protein in strains of animals that previously failed to respond adequately to other similar vaccines.
Inventors:
Michael A. Good et al. (NIAID)
Patent Status:
DHHS Reference No. E-161-1987/0 --
U.S. Patent No. 4,886,782 issued 12 Dec 1989
For Additional Information Please Contact: Robert M. Joynes J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)594-6565
Email: joynesr@mail.nih.gov
Fax: (301) 402-0220
